Differential sensitivities of retroviruses to integrase strand transfer inhibitors

Journal of Virology

Volumn 85, Issue 7, 2011, Pages 3677-3682

  Koh, Yasuhiro ^a   Matreyek, Kenneth A ^a   Engelman, Alan ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ELVITEGRAVIR; RALTEGRAVIR; ZIDOVUDINE;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; DNA TRANSPOSITION; DRUG POTENCY; GENETIC TRANSFECTION; HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRINAE; LONG INTERSPERSED REPEAT; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; RETROTRANSPOSITION; RETROVIRUS; ROUS SARCOMA ONCOVIRUS; SEQUENCE ALIGNMENT; VIRUS CELL INTERACTION; VIRUS INHIBITION; VIRUS RESISTANCE;

ANIMALS; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HUMANS; INTEGRASES; PRIMATES; PYRROLIDINONES; QUINOLONES; RETROELEMENTS; RETROVIRIDAE; VIRUS INTEGRATION;

ALPHARETROVIRUS; BETARETROVIRUS; GAMMARETROVIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; INTRACISTERNAL A-PARTICLES; PRIMATES; RICE STRIPE VIRUS; ROUS SARCOMA VIRUS;

EID: 79952580956     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02541-10     Document Type: Article

References (54)

1. Beck-Engeser, G. B., D. Eilat, T. Harrer, H. M. Jäck, and M. Wabl. 2009. Early onset of autoimmune disease by the retroviral integrase inhibitor raltegravir. Proc. Natl. Acad. Sci. U. S. A. 106:20865-20870.
2. Boeke, J. D., and J. P. Stoye. 1997. Retrotransposons, endogenous retroviruses, and the evolution of retroelements p. 343-435. In J. M. Coffin, S. H. Hughes, and H. E. Varmus (ed.), Retroviruses. Cold Spring Harbor Laboratory Press, Plainview, NY.
3. Bouchet, N., et al. 2009. First Mariner Mos1 transposase inhibitors. Mini Rev. Med. Chem. 9:431-439.
4. Chen, Z., et al. 2000. X-ray structure of simian immunodeficiency virus integrase containing the core and C-terminal domain (residues 50-293) - an initial glance of the viral DNA binding platform. J. Mol. Biol. 296:521-533.
5. Cooper, D. A., et al. 2008. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N. Engl. J. Med. 359:355-365.
6. Delelis, O., et al. 2009. The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation. Nucleic Acids Res. 37:1193-1201.
7. Dyda, F., et al. 1994. Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases. Science 266:1981-1986.
8. Engelman, A. 2010. Reverse transcription and integration, p. 129-159. In R. Kurth and N. Bannert (ed.), Retroviruses: molecular biology, genomics and pathogenesis. Caister Academic Press, Norfolk, United Kingdom.
9. Fransen, S., et al. 2009. Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J. Virol. 83:11440-11446.
10. Hare, S., S. S. Gupta, E. Valkov, A. Engelman, and P. Cherepanov. 2010. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 464:232-236.
11. Hare, S., et al. 2010. Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance. Proc. Natl. Acad. Sci. U. S. A. 107:20057-20062.
12. Hazuda, D. J., et al. 2000. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 287:646-650. (Pubitemid 30070911)
13. Horie, K., et al. 2007. Retrotransposons influence the mouse transcriptome: implication for the divergence of genetic traits. Genetics 176:815-827. (Pubitemid 46961087)
14. Izsvák, Z., M. K. Chuah, T. Vandendriessche, and Z. Ivics. 2009. Efficient stable gene transfer into human cells by the Sleeping Beauty transposon vectors. Methods 49:287-297.
15. Jenkins, T. M., D. Esposito, A. Engelman, and R. Craigie. 1997. Critical contacts between HIV-1 integrase and viral DNA identified by structurebased analysis and photo-crosslinking. EMBO J. 16:6849-6859. (Pubitemid 27503496)
16. Kobayashi, M., et al. 2008. Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants. Antiviral Res. 80:213-222.
17. Koh, Y., H. Haim, and A. Engelman. 2011. Identification and characterization of persistent intracellular human immunodeficiency virus type 1 strand transfer inhibitor activity. Antimicrob. Agents Chemother. 55:42-49.
18. Koh, Y., et al. 2003. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob. Agents Chemother. 47:3123-3129.
19. Krishnan, L., et al. 2010. Structure-based modeling of the functional HIV-1 intasome and its inhibition. Proc. Natl. Acad. Sci. U. S. A. 107:15910-15915.
20. Krishnan, L., et al. 2010. The requirement for cellular transportin 3 (TNPO3 or TRN-SR2) during infection maps to human immunodeficiency virus type 1 capsid and not integrase. J. Virol. 84:397-406.
21. Lewis, M. G., et al. 2010. Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy. Retrovirology 7:21.
22. Lu, R., et al. 2004. Class II integrase mutants with changes in putative nuclear localization signals are primarily blocked at a postnuclear entry step of human immunodeficiency virus type 1 replication. J. Virol. 78:12735-12746. (Pubitemid 39507782)
23. Mátés, L., et al. 2009. Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. Nat. Genet. 41:753-761.
24. McColl, D. J., and X. Chen. 2010. Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy. Antiviral Res. 85:101-118.
25. Melek, M., et al. 2002. Effect of HIV integrase inhibitors on the RAG1/2 recombinase. Proc. Natl. Acad. Sci. U. S. A. 99:134-137.
26. Métifiot, M., et al. 2010. Biochemical and pharmacological analyses of HIV-1 integrase flexible loop mutants resistant to raltegravir. Biochemistry 49:3715-3722.
27. Métifiot, M., C. Marchand, K. Maddali, and Y. Pommier. 2010. Resistance to integrase inhibitors. Viruses 2:1347-1366.
28. Mitsuya, H., et al. 1985. 3′-Azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc. Natl. Acad. Sci. U. S. A. 82:7096-7100.
29. Moebes, A., et al. 1997. Human foamy virus reverse transcription that occurs late in the viral replication cycle. J. Virol. 71:7305-7311. (Pubitemid 27391668)
30. Newman, R. M., et al. 2006. Balancing selection and the evolution of functional polymorphism in Old World monkey TRIM5alpha. Proc. Natl. Acad. Sci. U. S. A. 103:19134-19139.
31. North, T. W., G. L. North, and N. C. Pedersen. 1989. Feline immunodeficiency virus, a model for reverse transcriptase-targeted chemotherapy for acquired immune deficiency syndrome. Antimicrob. Agents Chemother. 33:915-919.
32. Nowotny, M. 2009. Retroviral integrase superfamily: the structural perspective. EMBO Rep. 10:144-151.
33. Ostertag, E. M., E. T. Prak, R. J. DeBerardinis, J. V. Moran, and H. H. Kazazian. 2000. Determination of L1 retrotransposition kinetics in cultured cells. Nucleic Acids Res. 28:1418-1423.
34. Paprotka, T., et al. 2010. Inhibition of xenotropic murine leukemia virus-related virus by APOBEC3 proteins and antiviral drugs. J. Virol. 84:5719-5729.
35. Pauwels, R., et al. 1990. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 343:470-474. (Pubitemid 120028562)
36. Plasterk, R. H., and H. G. van Luenen. 2002. The Tc1/mariner family of transposable elements, p. 519-532. In N. L. Craig, R. Craigie, M. Gellert, and A. M. Lambowitz (ed.), Mobile DNA II. ASM Press, Washington, DC.
37. Richardson, J. M., S. D. Colloms, D. J. Finnegan, and M. D. Walkinshaw. 2009. Molecular architecture of the Mos1 paired-end complex: the structural basis of DNA transposition in a eukaryote. Cell 138:1096-1108.
38. Roquebert, B., et al. 2008. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J. Antimicrob. Chemother. 62:914-920.
39. Ruprecht, R. M., L. G. O'Brien, L. D. Rossoni, and S. Nusinoff-Lehrman. 1986. Suppression of mouse viraemia and retroviral disease by 3′-azido-3′-deoxythymidine. Nature 323:467-469. (Pubitemid 16026279)
40. Shimura, K., et al. 2008. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J. Virol. 82:764-774.
41. Shimura, K., and E. N. Kodama. 2009. Elvitegravir: a new HIV integrase inhibitor. Antivir. Chem. Chemother. 20:79-85.
42. Singh, I. R., J. E. Gorzynski, D. Drobysheva, L. Bassit, and R. F. Schinazi. 2010. Raltegravir is a potent inhibitor of XMRV, a virus implicated in prostate cancer and chronic fatigue syndrome. PLoS One 5:e9948.
43. Smith, R. A., G. S. Gottlieb, and A. D. Miller. 2010. Susceptibility of the human retrovirus XMRV to antiretroviral inhibitors. Retrovirology 7:70.
44. Stetson, D. B., J. S. Ko, T. Heidmann, and R. Medzhitov. 2008. Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell 134:587-598.
45. Summa, V., et al. 2008. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J. Med. Chem. 51:5843-5855.
46. Tobin, G. J., W. H. Ennis, D. J. Clanton, and M. A. Gonda. 1996. Inhibition of bovine immunodeficiency virus by anti-HIV-1 compounds in a cell culture-based assay. Antiviral Res. 33:21-31.
47. Tsai, C. C., et al. 1995. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science 270:1197-1199.
48. Valkov, E., et al. 2009. Functional and structural characterization of the integrase from the prototype foamy virus. Nucleic Acids Res. 37:243-255.
49. Weichenrieder, O., K. Repanas, and A. Perrakis. 2004. Crystal structure of the targeting endonuclease of the human LINE-1 retrotransposon. Structure 12:975-986. (Pubitemid 38748770)
50. Witvrouw, M., et al. 1999. Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV. AIDS 13:1477-1483. (Pubitemid 29396678)
51. Yan, N., P. Cherepanov, J. E. Daigle, A. Engelman, and J. Lieberman. 2009. The SET complex acts as a barrier to autointegration of HIV-1. PLoS Pathog. 5:e1000327.
52. Yang, Z.-N., T. C. Mueser, F. D. Bushman, and C. C. Hyde. 2000. Crystal structure of an active two-domain derivative of Rous sarcoma virus integrase. J. Mol. Biol. 296:535-548.
53. Yergeau, D. A., et al. 2009. Transgenesis in Xenopus using the Sleeping Beauty transposon system. Dev. Dyn. 238:1727-1743.
54. Zhang, F., T. Hatziioannou, D. Perez-Caballero, D. Derse, and P. D. Bieniasz. 2006. Antiretroviral potential of human tripartite motif-5 and related proteins. Virology 353:396-409.